CLIA solutions are widely applied in the detection of chronic diseases, such as infectious disease, autoimmune disease, cardiovascular disease, diabetes, obesity, and cancer.
The increasing awareness about the early diagnosis of chronic diseases and the rising drug discovery and development activities by pharmaceutical companies are considered to be the high-impact rendering drivers for the market.
Chemiluminescence is widely used in clinical practice. Chemiluminescence is a diagnostic method that uses specific reactions between antigens and antibodies to determine the concentration of disease markers in the body, so as to judge the state of the human body, and is widely used in infectious diseases, heart diseases, tumors, pregnancy detection, etc.
Immunoreaction. Antigens enter the body and stimulate the body's immune system to produce an immune response, which is called an immune response. The immune response includes three consecutive phases of sensing, reacting and effect on the antigen substance.
Immunoassay (IA). In clinical testing, antibodies or antigenic substances in body fluids are analyzed with known antigen or antibody detection based on the specific reaction of antigen and its paired antibody.
High specificity. Antigen-antibody binding essentially occurs only between the antigen determinant of the antigen and the antigen-binding site of the antibody. These two are complementary in chemical structure and spatial configuration, consequently, antigen-antibody reactions have a high degree of specificity. The high specificity of antigen-antibody responses is the basis of immunological testing.
High affinity. The process of antigen and antibody binding to form antigen-antibody complex is a kind of dynamic equilibrium. The antigen binding point of the high-affinity antibody and the determinant of the antigen are suitable in the spatial configuration, and the two are firmly bound and difficult to dissociate.
1) The concentration of the detected substance is low (μg/L—pg/L), resulting in high precision requirements for the entire detection system, and the instrument and reagent system are closed.
2) The entire detection process has many steps and is difficult to automate.
3) A variety of cutting-edge technologies including biology, chemistry, physics, optics and other disciplines are indispensable.
Compared with other immunodiagnostic methods, chemiluminescence has become the mainstream of immunodiagnosis because of its systematic advantages in safety, automated operation, test accuracy, and test speed, and has surpassed other technologies in performance.
In order to adapt to the development and seize the great market, EasyDiagnosis has broken through technical difficulties and launched several platforms. One of them worth mentioning is the CF10 Chemiluminescence Platform.
CF10 is a great combination of easy operation and accurate results, helps elevate the healthcare experience. Its innovative single-test reagent strip design ensures instant usability, eliminating any wastage. With the ability to handle whole blood specimens, CF10 seamlessly combines the convenience of POCT with the precision of chemiluminescence. Being able to quantitatively detect inflammatory markers, cardiac markers, brain injury markers, etc. It is applicable to clinical laboratories and departments, including emergency room, ICU, CCU, etc.